Kelly Broster is a postdoctoral LC-MS scientist at Cancer Research UK, with a PhD in Cancer Research and a Masters in Biomedical Sciences. She specializes in biopharmaceutical development. With a background in protein mass spectrometry, Kelly’s expertise spans drug discovery, cancer biology, and quantitative proteomics, with a strong focus on developing biomarker assays for patient stratification and treatment monitoring. She is currently Senior Manager, Market Development and Collaborations at Thermo Fisher Scientific, where she leads initiatives focused on enabling customers to accelerate biopharmaceutical development and optimize analytical workflow.